Theseus Pharmaceuticals (THRX) announced it will present a poster on next-generation EGFR inhibitors at the AACR 2022 Annual Meeting from April 8-13 in New Orleans. The poster will detail the characterization of selective EGFR inhibitors that target T790M and C797S mutations, which are prevalent in patients resistant to current therapies. These innovations may significantly impact non-small cell lung cancer treatment, as EGFR mutations occur in 10-50% of cases. The presentation will be made by Dr. Wei-Sheng Huang on April 12.
Theseus Pharmaceuticals (NASDAQ: THRX) announced that CEO Tim Clackson will participate in the virtual 11th Annual SVB Leerink Global Healthcare Conference from February 14-18, 2022. Clackson's fireside chat is scheduled for February 18 at 2:20 PM ET. A live webcast of the event will be available on the company's investor relations website and archived for 30 days. Theseus focuses on innovative cancer therapies, specifically developing pan-variant TKIs to combat cancer resistance. Their lead candidate, THE-630, targets advanced gastrointestinal stromal tumors (GIST).
Theseus Pharmaceuticals (NASDAQ: THRX) announced that its lead candidate, THE-630, has received orphan drug designation from the FDA for treating advanced gastrointestinal stromal tumors (GIST). This designation aims to provide better therapeutic options for patients with GIST who have developed resistance to standard treatments. GIST affects 4,000 to 6,000 patients annually in the U.S., with 80% of cases linked to mutations in the KIT gene. Orphan drug status offers various benefits, including marketing exclusivity and tax credits for clinical costs.
Theseus Pharmaceuticals (THRX) announced significant updates and financial results for Q3 2021. The company achieved FDA IND clearance for its lead therapy, THE-630, targeting advanced gastrointestinal stromal tumors (GIST). Successful IPO raised approximately $178.8 million in October 2021. Research and Development costs were $5 million for Q3, with a net loss of $7.4 million, or $5.16 per share. The company expects its cash reserves, including IPO proceeds, to sustain operations until mid-2024.
Theseus Pharmaceuticals (NASDAQ: THRX) will participate in the 12th Annual Jefferies London Healthcare Conference from November 16-19, 2021. Tim Clackson, Ph.D., President and CEO, will host a virtual fireside chat, with a pre-record available starting November 18 at 8:00am GMT. This event will showcase Theseus' focus on targeted therapies for cancer treatment, including the lead candidate, THE-630, for advanced gastrointestinal stromal tumors. Archived webcasts will be accessible on the Jefferies website for 30 days after the event.
Theseus Pharmaceuticals has priced its initial public offering at $16.00 per share, totaling $160 million in gross proceeds. The offering consists of 10,000,200 shares and includes a 30-day option for underwriters to purchase an additional 1,500,030 shares. Trading on the Nasdaq under the ticker THRX is set to begin on October 7, 2021, with the expected closing date on or around October 12, 2021. Jefferies, SVB Leerink, and Cantor serve as joint book-running managers for this offering.